COVID-19 vaccine efficacy against variants
| Pfizer-BioNTech | |
| Original virus | 95% |
| B.1.1.7 | Same efficacy |
| B.1.351 | Reduced antibody levels |
| P.1 | Same efficacy |
| Moderna | |
| Original virus | 94% |
| B.1.1.7 | Same efficacy |
| B.1.351 | Reduced antibody levels |
| P.1 | More data needed |
| J&J | |
| Original virus | 72%* |
| B.1.1.7 | Same efficacy |
| B.1.351 | Reduced efficacy (in South Africa trials) |
| P.1 | Reduced efficacy (in Latin America trials) |
| AstraZeneca | |
| Original virus | 60-90% |
| B.1.1.7 | Same efficacy |
| B.1.351 | Reduced efficacy |
| P.1 | Same efficacy |
| Sinovac | |
| Original virus | 50% |
| B.1.1.7 | Same efficacy |
| B.1.351 | Reduced antibody levels |
| P.1 | Reduced antibody levels |
| Original virus | B.1.1.7 | B.1.351 | P.1 | |
|---|---|---|---|---|
| Pfizer-BioNTech | 95% | Same efficacy | Reduced antibody levels | Same efficacy |
| Moderna | 94% | Same efficacy | Reduced antibody levels | More data needed |
| J&J | 72%* | Same efficacy | Reduced efficacy (in South Africa trials) | Reduced efficacy (in Latin America trials) |
| AstraZeneca | 60-90% | Same efficacy | Reduced efficacy | Same efficacy |
| Sinovac | 50% | Same efficacy | Reduced antibody levels | Reduced antibody levels |
